Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

BAY-1747846

Generic Name: BAY-1747846

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Study to Learn More About the Safety and the Level of BAY 1747846 in Body Given as Injection Into the Vein at Increasing Single Doses in Japanese Healthy Male Participants

Phase 1

Completed

Posted: 2023/11/09

Sponsor:Bayer

ID:NCT06125366

A Study to Evaluate the Pharmacokinetics (How it Moves Into, Through and Out From the Body) of a New Gadolinium-based Contrast Agent (GBCA) After Injection and How Safe it is in Participants With Normal and Impaired Renal Function

Phase 1

Completed

Posted: 2021/09/30

Sponsor:Bayer

ID:NCT05061979

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Bayer to Showcase Advanced Radiology Portfolio and Novel Contrast Agent at ECR 2025

3 months ago

Bayer will present pivotal Phase III data for gadoquatrane, its investigational low-dose contrast agent for MRI, demonstrating comparable efficacy to standard macrocyclic agents at 60% lower gadolinium dose.

Bayer's Gadoquatrane Achieves Positive Phase III Results with Reduced Gadolinium Dose

5 months ago

Bayer's investigational MRI contrast agent, gadoquatrane, met primary and secondary endpoints in Phase III QUANTI studies.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy